![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Philadelphia Chromosome - 27 Studies Found
Recruiting |
: A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults : Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia : 2015-11-19 :
|
Recruiting |
: Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults : Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia : 2015-11-25 |
Suspended |
: Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) : Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) : 2010-10-15 : Drug: Imatinib Mesylate patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in c |
Suspended |
: Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) : Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+) : 2010-10-14 : Drug: Imatinib Mesylate Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maxi |
Terminated |
: Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia :
|
Terminated |
: TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia :
|
Recruiting |
: Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older :
|
Completed |
: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response :
|
Completed |
: Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase : CML in Chronic Phase : 2010-02-01 : Drug: Nilotinib Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib |
Terminated |
: Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) :
: Other: Comparator: Biomarker evaluation Patients on standa |